The Pediatric African League against Rheumatism (PAFLAR) initiative has published its guidelines for the diagnosis and treatment of polyarticular juvenile idiopathic arthritis (pJIA).The ACR last published recommendations for JIA (for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis) were in n 2019.
Dr. John Cush RheumNow
1 year 4 months ago
Glucocorticoid Toxicity Index
Dr. John Stone has led the effort to develop the GTI - glucocorticoid toxicity index. In this review article he acknowledges the need and benefit of steroids, but details a novel means to identify and limit the untoward effects of glucorticoids… https://t.co/xR8D4Jpjfv https://t.co/LyfHrbneTO
Dr. John Cush RheumNow
1 year 4 months ago
Comprehensive review of the management of knee osteoarthritis - topicals, analgesics, narcotics, intraarticular, metabolic, nutraceuticals, TENS, acupuncture and biologics. https://t.co/SEyG4IQ0bh https://t.co/f6UY4hEl18
Dr. John Cush RheumNow
1 year 4 months ago
Single Center study of 112 RA pts from Morocco used machine learning (ML) logistic regression model & identified #Depression in 48% (HADS score >8) w/ 76.5% accuracy, 72.2% precision, 81.2% recall, and an area under the receiver operating characteristic curve (ROC AUC) of… https://t.co/LBvdVEzDGJ https://t.co/bYLqsFagbR
Dr. John Cush RheumNow
1 year 4 months ago
2024 Rheumatology Year in Review
2024 was a year of surprising new growth in technology, with the expansion of new therapeutic options for many patients and clinicians.
https://t.co/XuEG8Hrc9e https://t.co/ja5OoZXdWo
Dr. John Cush RheumNow
1 year 4 months ago
Cardiovascular and Fracture Risk with Denosumab Versus Bisphosphonates in Dialysis Patients
Annals of Internal Medicine has published a Japanese administrative claims database study showing that, compared with oral bisphosphonates (BIS), denosumab (DEN) lowered fracture risk… https://t.co/kNqGNTrsAF https://t.co/xgCeaMDT1N
Dr. John Cush RheumNow
1 year 4 months ago
Increased Mortality In Arthritis Patients with COPD
A new study published in the January 2025 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open-access journal, finds that people with chronic obstructive pulmonary disease… https://t.co/6WCtfcrSaq https://t.co/ydVtBxqy37
Dr. John Cush RheumNow
1 year 4 months ago
Congress Passes Fiscal Year 2025 Funding for Lupus Programs, including
- $10 million Natl Lupus Patient Registry at CDC
- $2 million Natl Lupus Training, Outreach, CTE Program
- $47.08 billion for the National Institutes of Health SLE prgs https://t.co/BCs3lGdrXK https://t.co/58PkKG9ay6
Dr. John Cush RheumNow
1 year 4 months ago
Stelara Biosimilar Steqeyma Launches at 85% Discount https://t.co/2ZR7LMq1JT https://t.co/coHj1jh8JB
Dr. John Cush RheumNow
1 year 4 months ago
Japanese study of hip replacements (THA) - #RA pts undergoing THA at higher risk for dislocation and reoperation. Retrosp database study of THA - matching 3,951 RA vs 11,853 OA. w/ RA incr risk of dislocation (OR 2.8) & reoperation (OR: 2.25). No diff infx, Fx, VTE, death… https://t.co/Mz8niRlFaa https://t.co/mgcXTnw5Al
Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively.
A randomized clinical trial has shown that oral mizoribine, a common immunosuppressant in Japan, was noninferior to intravenous cyclophosphamide (CTX) as induction therapy in patients with active lupus nephritis.
Dr. John Cush RheumNow
1 year 4 months ago
Is better earlier imaging needed for axial #PsA? to better visualize spinal ligamentous soft tissue Spinal entheseal soft tissue and contiguous ligamentous tissues are poorly visualized on MRI in early inflammatory back pain pts. https://t.co/4w4CamMT4I https://t.co/RQigMjMe9n
Dr. John Cush RheumNow
1 year 4 months ago
Alpha-gal syndrome (AGS) is a (Lone Star) tick-borne allergy to the galactose-α-1,3-galactose carbohydrate, found in mammalian meat/products; Sxs (hives, itching, swelling, and GI issues) present 2-8 hrs after meat & be life-threatening. Time to Dx has dropped considerably, w/… https://t.co/p1M9Qaf1jz https://t.co/jTJzq7YtVJ
Dr. John Cush RheumNow
1 year 4 months ago
Sobi announced it has submitted to FDA a supplemental (sBLA) for Gamifant (emapalumab-Izsg) for use in adult & kids w/ hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in Still’s disease with an inadequate response glucocorticoids, or with recurrent… https://t.co/a3I1fzHLdl https://t.co/WTFAs5PLWF
